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Radiation oncologyRadiation therapy is a standard therapeutic option in the post-operative setting for early breast cancer
patients after breast conserving surgery, providing a substantial benefit in reducing the risk of local
relapse with a consequent survival gain. Nevertheless, the reduction in the burden related to treatment
is becoming crucial in modern oncology for both local and systemic therapies and investigational efforts
are being put forward by radiations oncologists to identify a subset of women at very low risk to be
potentially omitted from post-operative irradiation after breast conservation. Clinical factors, classical
pathological parameters and new predictive scores derived from gene expression and next generation
sequencing techniques are being integrated in the quest toward a reliable low-risk profile for breast can-
cer patients. We herein provide a comprehensive overview on the topic.
 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an
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Postoperative whole breast irradiation (WBI) is currently con-
sidered as a standard option for most early-stage breast cancer
patients (EBC) after breast conserving surgery (BCS) [1]. As shown
in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
meta-analysis, WBI halves the 10-year rate of any breast cancer
recurrence (from 35.0% to 19.3% with an absolute reduction of
15.7%) and reduces the 15-year breast cancer-related mortality
by about one sixth (from 25.2% to 21.4% with an absolute reduction
of 3.8%) [2]. The addition of a boost dose to the tumor bed provides
a further benefit on the risk of local recurrence, with an absolute
reduction particularly evident in patients with unfavorable risk
factors such as young age (<51 years), high grade tumors and
threatened surgical margins [3,4]. The proportional benefit of
WBI on both loco-regional relapse and breast cancer mortality is
stable among different subsets of women. Conversely, the absolute
risk reduction is, to some extent, proportionally affected by factors
related to both patient and tumor [3]. Overall, in node negative
patients, a subgroup generally at lower risk of disease recurrence,
the 10-year rate of any breast cancer recurrence is reduced from
31.0% to 15.6% with an absolute risk reduction of 15.4%, while
the 15-year breast cancer-related mortality from 20.5% to 17.2%,
with an absolute risk reduction of 3.3% [3]. After stratification of
this subgroup of patients according to age, tumor grade,
estrogen-receptor status, tamoxifen use and extent of surgical
excision, those with a 10-year absolute risk of recurrence at
10 years below 10%, showed an absolute reduction in the 15-
year risk of death due to breast cancer of 0.1%. [3]. This observation
prompted the need to carefully evaluate and tailor the treatment
burden for this subset of patients, particularly the need for adju-
vant endocrine therapy and the clinical indication of WBI after
BCS. For these patients, the chance to decrease the treatment
intensity might be important to avoid unnecessary acute and late
toxicity and to optimize resources allocation for healthcare provi-
ders [5]. Whether to de-escalate endocrine therapy or radiation
still needs further clinical investigation.
To decrease the radiotherapy burden in breast cancer patients
several options are available, including the reduction in treatment
volumes using partial breast irradiation, the decrease in overall
treatment time with accelerated hypofractionation and the refin-
ing of radiotherapy delivery techniques (IMRT, VMAT, IGRT, proton
therapy) to lower normal tissue dose and to increase the therapeu-
tic index [6–10]. Another option is the complete omission of WBI
after BCS, with the administration of adjuvant endocrine therapy,
while the avoidance of both RT and hormonal manipulation after
BCS is still to be considered as investigational [11]. RT omission
after BCS has been explored in several randomized phase III trials,
with heterogeneous eligibility criteria, leading to somehow argu-
able results and consequent confounding interpretations. The ade-
quate selection of patients at very low risk of recurrence is
therefore crucial and needs robust clinical evidence. We herein
provide a comprehensive review on the omission of WBI after
BCS, with a focus on patient- and tumor-related factors to be taken
into account for a reliable clinical decision-making process.2. Establishing the role of breast conservation and hormonal
therapy
The role of BCS in the setting of EBC has been established in
seminal randomized phase III trials performed in the 70–80s in
both United States and Europe. The Milan I trial (1973–1980) ran-
domized a total of 701 patients with <2 cm invasive breast cancer
and no palpable nodes in the axilla to receive Halsted radical mas-
tectomy vs quadrantectomy + axillary dissection and WBI to theresidual breast [12]. At 20-year follow up, the cumulative inci-
dence of ipsilateral breast tumor recurrence (IBTR) was 2.3% in
the mastectomy group and 8.8% for breast conservation. No differ-
ences in overall survival (OS) were seen (41.2% vs 41.7%) [13]. Sim-
ilarly, the NSABP B-06 trial (1976–1978) explored the role of local
excision with or without radiation in EBC. A total of 1.843 patients
with invasive breast cancer 4 cm was randomized to receive total
mastectomy vs lumpectomy vs lumpectomy + WBI (with axillary
dissection) [14]. At 20-years the cumulative incidence of IBTR
was 14.3% with lumpectomy and WBI, but no differences were
found in terms of disease-free survival (DFS) and OS [15]. Similar
conclusions in favor of BCS came out from the European Organiza-
tion for Research and Treatment of Cancer (EORTC) 10810 and the
Danish Breast Cancer Cooperative Group (DBCG)-82TM trials
[16,17].
In the same period, the benefit of adjuvant endocrine therapy
was reported in EBC patients. The NSABP-B14 trial was a random-
ized, double-blind placebo-controlled trial investigating the role of
adjuvant tamoxifen in 2.644 women with invasive breast cancer,
negative axillary nodes and positive estrogen receptors (ER) [18].
A significant prolongation in DFS was seen in the tamoxifen group,
particularly in younger women (49 years), which was maintained
at 15 years [18,19]. Moreover, a reduction in breast-cancer mortal-
ity was seen in studies as the DBCG 77c trial and the EBCTCGmeta-
analysis [20,21]. The role of endocrine therapy in reducing the rate
of any breast recurrence pushed researchers to test the hypothesis
that WBI could be omitted after BCS. The lumpectomy only arm of
the NSABP-B06 trial had a high rate of IBTR (27.9% at 5 years and
39.2% at 20 years) [14,15]. But eligibility criteria included tumor
up to 4 cm in the largest dimension. Hence, clinical research
addressed, at least in some trial, the option to avoid WBI in a
patient population harboring smaller tumors.3. First generation of phase III trials investigating WBI omission
The first generation of prospective randomized phase III clinical
trials investigated WBI omission after BCS with very broad inclu-
sion criteria and a consequently vague profile of patients at low
risk of recurrence [22–32] (Table 1). For example, the Ontario Clin-
ical Oncology Group (OCOG) trial (1984–1989) randomized 837
node negative breast cancer patients, after lumpectomy and axil-
lary lymph node dissection, to receive WBI (416 patients) or no
radiation (421 patients) [22]. Tumors were <4 cm in size and resec-
tion on free microscopic margins. A dose of 40 Gy in 16 fractions
over 3 weeks was given for WBI, followed by a 12.5 Gy boost dose
to the tumor bed in 5 fractions. No endocrine therapy was given.
After a median observation time of 43 months, the IBTR rate was
5.5% with WBI and 25.7% without [22]. After a median follow up
of 91 months, the IBTR rate was 11% with WBI and 35% without,
while no difference in OS was seen [23]. Young age (<50 years),
tumor size (>2 cm) and poor tumor nuclear grade were found to
be predictors of IBTR. Nevertheless, a clearly identified low risk
subgroup could not be identified [23].
Other trials explored the option of omitting WBI in the context
of an extended surgery to the breast compared to lumpectomy. The
Milan III trial (1987–1989) enrolled a total of 567 patients (age: 
70; tumor diameter <25 mm), after quadrantectomy (extensive
breast resection including the overlying skin and the underlying
fascia) and axillary dissection to receive immediate WBI (294
patients) or no radiation (273 patients). Radiation consisted of
50 Gy in 25 fractions WBI followed by a conventionally fraction-
ated boost up to 10 Gy. Patients having pathological nodal involve-
ment were given adjuvant chemotherapy in case of estrogen
receptor negative tumors (96/567; 17%) or tamoxifen if positive
(68/567; 12%). Long-term results showed a 10-year crude cumula-
Table 1
First generation trials exploring radiotherapy omission after breast conservation in unselected breast cancer patients.
Pts: patients; yrs: years; Adjuv treat: adjuvant treatment; IBTR: ipsilateral breast tumor recurrence; OS: overall survival; FU: follow up; mos: months; Lump: lumpectomy;
AD: axillary dissection; Quad; quadrantectomy; res: resection; Tam: tamoxifen; CT: chemotherapy; RT: radiotherapy; diff: difference; CSS: cancer specific survival.
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OS was detected at 10 years [24,25]. Age was found to be a signif-
icant factor affecting the rate of IBTR [25]. The Uppsala-Orebro
Breast Cancer Study Group Trial (1981–1988) randomized, a total
of 381 stage I breast cancer patients (aged <80, with a unifocal
node negative tumor sized 2 cm), after standardized sector resec-
tion (dissection of the breast gland up to its peripheral aspects in
the plane of Scarpa’s fascia, included in the specimen, and down
to the pectoralis muscle) and axillary dissection, to receive (184
patients) or not (197 patients) WBI, consisting of 54 Gy/27 frac-
tions with no boost to the surgical bed [26,27]. No adjuvant endo-
crine therapy was given. The IBTR rate were 2.9% in the WBI arm
and 7.6% in the no radiation arm at 3 years, 3.3% vs 18.4% at 5 years
and 8.5% vs 24.0% at 10 years [27–29]. No difference in OS was seen
at 10 years. Patients aged >60 years, without comedo or lobular
cancer or without the mammographic appearance of a stellate
lesion with microcalcification were found at low risk of recurrence
(<6% at 5 years) [30].
Tumors size was taken into account in both the Milan III and
Uppsala-Orebro trials in which patients were accrued if having
tumors sized <25 mm and 20 mm, respectively. Another study
accounting for tumor dimension is the NSABP B-21 trial (1989–
1998), which enrolled a total of 1.009 patients, with a diagnosis
of invasive breast tumor 1 cm, negative axillary nodes and free
tumor margins after lumpectomy and axillary dissection [31].
Patients were randomized to receive adjuvant tamoxifen only for
5 years (336 patients), WBI (50 Gy/25 fractions over 5 weeks + b
oost as per center’s policy) and placebo (336 patients) or WBI + ta-
moxifen (337 patients). At 8 years, the cumulative incidence of
IBTR was 16.5% with exclusive tamoxifen, 9.3% with WBI only
and 2.8% with WBI and tamoxifen. The advantage in reducing IBTR
for WBI was observed regardless of ER status. Patients treated with
tamoxifen (with or without WBI) had a lower rate of contralateral
breast cancer (HR: 0.45; 95%). No difference in OS was seen [31].
Tumors arising within a radial scar, those of tubular histology or
with no poor tumor grade or ductal carcinoma in situ component
were found to be at lower risk [32].
The role of adjuvant endocrine therapy as a subsidiary to WBI
was investigated also in the Scottish trial (1985–1991), which ran-
domized 585 patients (age: <70 years, with invasive breast cancer
4 cm, node negative and no fixation of primary tumor) after localexcision and either axillary sampling (3–4 nodes) or clearance
(levels I-III), to receive postoperative WBI (291 patients) or no fur-
ther local treatment (294 patients) [33]. All subjects were given
adjuvant systemic treatment with oral tamoxifen in case of ER pos-
itive tumors or 6 cycles chemotherapy for negative cases. At a
median follow up time of 5.7 years, IBTR rate was 5.8% after WBI
and 24.5% with no radiation. No differences in OS were seen. The
advantage of WBI in terms of IBTR rate was seen irrespective of
ER status [33].
In the aforementioned trials, the population of patients
included was widely heterogeneous, selected mainly by tumor
size, unifocality, negative axillary nodes and free-resection mar-
gins after BCS. Age was not used as a selection criterion and hence
no focus on an elder population was addressed. The same consid-
eration can be made for hormonal receptor status whose evalua-
tion was yet to be completely established at the time. A trial
with strict selection criteria was the Finnish study which enrolled
patients with unifocal tumor sized <2 cm, well-or moderately-
differentiated (G1-G2), with positive progesterone receptor (PgR)
and no extensive intraductal component [34]. The broad spectrum
of patient, tumor and treatment characteristics allowed for subset
analyses to extrapolate factors predictive of local relapse and
patient subgroups at low risk. Age, tumor size, poor differentiation
grade, histology were identified, but a clear low risk profile was
hardly identified.
This was evident in the SweBCG 91 RT trial (1991–1997), where
1.187 patients with T1-T2 N0 M0 disease were randomized, after
sector resection and axillary dissection, to receive (593 patients)
or not (594 patients) WBI (48–54 Gy in 24–27 fractions over
5 weeks) [35]. Adjuvant tamoxifen or CMF chemotherapy were
prescribed in stage II patients. At 5-years, the cumulative incidence
of IBTR was 14% for patients having WBI omitted and 4% for those
receiving radiation, while at 15.6 years, it was 23.9% and 11.5%
respectively [35,36]. Recurrence-free survival was lower for
patients not receiving WBI (51.7% vs 60.4%), while OS did not sig-
nificantly differ. In this trial the 15-year cumulative incidence of
IBTR in patients not receiving radiation ranged from 16.7% to
28%, depending on age, tumor size, hormonal receptor status and
diagnostic methods. In low-risk patients, aged >64 years, with a
primary tumor sized <21 mm and having positive ER and PgR,
the cumulative reduction in IBTR rates following WBI was higher
Table 2
Trials investigating the omission of radiotherapy in patients selected by clinical and pathological characteristics.
Pts: patients; HR: hormonal receptor; LR: local relapse; OS: overall survival; FU: follow up; mos: months; Lump: lumpectomy; WE: wide excision; AD: axillary dissection; AS:
axillary sampling; BCS: breast conserving surgery; SLNB: sentinel lymphnode biopsy; NA: not available; ER: estrogen receptor; PgR: progesteron receptor; NR: not reported;
fav. hist.: favourable histology; res: resection; fa LVI: limphovascular invasion; EIC: extensive intraductal component; TAM: tamoxifen; RT: radiotherapy; AI: aromatase
inhibitor.
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the radiation arm) [36].
Clinical features of breast cancer at diagnosis still represent
major prognostic factors for EBC. However, it is clear nowadays
that they could not represent anymore the only assessed factors
to correctly stratify patients for the risk of relapse and allocate
them to the most appropriate and tailored treatment approach.4. Phase III trials investigating selective WBI omission in
patients at low risk
Trials of second generation tried to create a more reliable profile
of EBC patients at low risk of recurrence, with a systematic use of
age thresholds, hormonal receptor status and other factors such as
tumor grade, lymph vascular extension, extensive intraductal com-
ponent, for precise allocation [37–46] (Table 2). Pre-established
selection criteria allowed for a better targeting of the patient pop-
ulation but at the same time narrowed the chance to perform
robust subset analyses.
In the Cancer and Leukemia Group B (CALGB) 9343 trial (1994–
1999), a total of 636 patients were randomized after lumpectomy
or wide local excision and axillary sampling or dissection to receive
adjuvant tamoxifen alone (319 patients) or tamoxifen + WBI (317
patients) [37]. Eligibility criteria included women aged 70 years
with stage I invasive breast cancer (cT1N0M0) with positive ER.
WBI was delivered up to 45 Gy in 25 fractions over 5 weeks,
including level I-II axillary nodes. A sequential electron boost of
14 Gy in 7 fractions was given. Tamoxifen was administered for
5 years [37]. At 5-years, the rate of IBTR was 1% in the group sub-
mitted to WBI and tamoxifen and 4% in the tamoxifen alone group,
while at a median follow up of 12.6 years it was 2% and 9%, respec-
tively [37,38]. At 154 months, the time to loco-regional recurrence
was longer for the WBI + tamoxifen group, while OS did not signif-
icantly differ. No subgroup analysis was performed [38].
In the Toronto and British Columbia trial (1992–2000), a total of
769 patients was randomized after BCS and axillary dissection,
sampling or clinical assessment, to receive adjuvant tamoxifenalone (386 patients) or tamoxifen + WBI (383 patients) [39]. Inclu-
sion criteria comprised women aged 50 years with a node nega-
tive invasive breast cancer sized <5 cm (T1-T2 stage). Axillary
dissection or sentinel lymph node biopsy were performed except
in women older than 65 years, who were considered eligible also
if staged negative on the axilla with clinical criteria. WBI was deliv-
ered with a hypofractionated schedule of 40 Gy in 16 fractions over
3–4 weeks, followed by a 12.5 Gy/5 fractions boost to the tumor
bed. Adjuvant tamoxifen was given for 5 years. Five-year IBTR rate
was 7.7% in the group receiving exclusive tamoxifen and 0.6% in
the group submitted to WBI and tamoxifen. At 8 years, the rates
increased to 17.6% and 3.5%, respectively [39]. The addition of
WBI to tamoxifen significantly improved 5-year DFS compared to
tamoxifen alone (91% vs 84%). Five-year OS was not significantly
different [39].
In the PRIME II trial (2003–2009), a total of 1.326 patients was
randomized after BCS and pathological axillary staging (sentinel
lymph node biopsy, four-node lower axillary node sampling, axil-
lary dissection) to receive WBI (658 patients) or no further local
treatment (668 patients) on top of planned adjuvant endocrine
therapy [40]. Eligibility criteria included women aged 65 years or
more with EBC at low risk of local recurrence (cT1-T2N0 tumor
sized 3 cm with clear resection margins and hormonal receptor
expression). Patients with grade 3 tumors or lympho-vascular
invasion were allowed but not those with both risk factors. Radia-
tion was given to the whole breast up to 40–50 Gy in 15–25 frac-
tions over 3–5 weeks. A boost to the tumor bed was allowed with
electrons or iridium implants up to 10–15 Gy. After a median fol-
low up of 60 months, IBTR rate was 1.3% in patients submitted to
WBI and 4.1% in those who were not. No difference in OS was
observed. The absolute risk reduction with the addition of WBI
was 2.9% at 5 years. No risk factors predictive for local recurrence
were found (tumor size or grade, age, margin status, LVI+, ER sta-
tus). The only variable predictive of IBRT was the omission of
WBI (HR: 4.87) [40].
The British Association of Surgical Oncology (BASO) II study was
a randomized clinical trial with a 2  2 factorial design evaluating
the effect of the addition of WBI or tamoxifen or both in EBC after
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ance [41]. Patient profile was chosen according to the Nottingham
Prognostic Index which stratifies risk groups in different prognos-
tic categories [42]. Eligibility criteria included patients <70 years of
age with node negative invasive breast cancer sized 20 mm, with
histological grade 1 or specific good prognosis histology (muci-
nous, papillary, tubular, cribriform) and no evidence of lympho-
vascular invasion. The four available treatment arms included
BCS only, BCS + WBI, BCS + tamoxifen or BCS + WBI + tamoxifen.
At a median observation time of 121 months, the cumulative inci-
dence of IBTR was 10.2% for patients not receiving radiation (BCS
only and BCS + tamoxifen group), 3.9% for those receiving radio-
therapy (BCS + WBI and BCS + WBI + tamoxifen groups), 11.7%
for those not receiving tamoxifen (BCS and BCS + WBI groups)
and 4.2% for patients receiving tamoxifen (BCS + tamoxifen and
BCS + WBI + tamoxifen groups). The annual rate of IBTR was 0.4%
in patients receiving WBI or tamoxifen, 1.2% and 1.3% in those hav-
ing WBI or tamoxifen omitted, respectively. The risk of local recur-
rence was reduced by the addition of WBI (HR: 0.37) or tamoxifen
(HR: 0.33). The use of both WBI and tamoxifen was associated to a
non-significant improvement in OS [41].
In this generation of trials the option of WBI omission was
addressed to a population selected by patient characteristics such
as age (65 or  70 as in the PRIME II and CALGB 9343 trials),
and tumor features such as size (T1 or favorable T2 tumors, except
for the Toronto and British Columbia trial), hormonal receptor sta-
tus (positive in most of the studies) and other histologic charcter-
istics such as tumor grade, lymph vascular invasion and extensive
intraductal component (Table 2). Subset analysis, such as the one
performed in the PRIME II trial, were not able to identify predictive
factors for IBTR in this selected setting of patients [40]. The addi-
tion of either WBI or tamoxifen after BCS lowers the local recur-
rence rate, with comparable effects as seen in the BASO II and
German Breast Cancer Study Group trials [41,44]. Combining WBI
and Tamoxifen has addictive effect in preventing IBTR ’[37,39].
No influence on OS was detected in any trial by the addition of
WBI.
There is a growing burden of knowledge concerning the impact
of tumor’s biology on disease outcome. Phenotypical biology signa-
ture might not be able to overcome the impact on prognosis of
clinical features, but should be strongly integrated in the decision
making process, in order to avoid over- or under-treatment and
to implement personalized radiotherapy approaches.
5. Prospective trials using biomarker-based approaches to
identify low risk patients
Different molecular subtypes of breast cancer can be identified
through gene expression profiling and next generation sequencing
techniques. This can help identifying specific clinical behaviors and
different responses to therapy [47,48]. Approaches such as
immunohistochemistry (IHC) can provide parameters for major
intrinsic biologic subtype determination. This can be enriched with
information predicting patient’s risk for local and distant relapse
[3,49]. Liu et al recently performed an analysis on patients accrued
in the Toronto-British Columbia trial, using a 6-IHC marker subtyp-
ing panel to explore the predictive ability of intrinsic subtyping
with respect to the benefit of WBI and to identify a subgroup of
patients at low-risk of local recurrence [50]. Luminal subtypes
were shown to have a lower benefit if submitted to WBI (HR: 0.4
for Luminal A-like and 0.51 for Luminal B-like) when compared
to high-risk subtypes (Luminal HER2 positive, HER-enriched, basal
like and triple-negative non-basal type). In a targeted evaluation
on low-risk patients (over 60 years of age, tumors below 2 cm in
size and Grade 1–2) with Luminal A subtype, the 10-year IBTR rate
was 3.1% vs 11.8% for high-risk patients [50].Tumor subtyping assessed through IHC, genomic expression or
signature assays is a promising strategy to identify a subgroup of
low-risk women to whom spare radiotherapy after BCS. Different
studies are presently investigating this approach (Table 3).
The IDEA (Individualized Decisions for Endocrine Therapy) trial
(NCT02400190) is a multicentric prospective single-arm observa-
tional study (University of Michigan Cancer Center) assessing
loco-regional relapse rate after BCS in post-menopausal women
(age:50–69), planned to undergo post-operative endocrine therapy
(either tamoxifen or aromatase inhibitors) [51]. Inclusion criteria
comprise unifocal disease, stage cT1 N0 M0 with negative axilla,
excision margins 2 mm, hormonal receptor positive and HER2
negative. The study relies on a gene expression signature based
on the 21-gene recurrence score assay OncotypeDX (Genomic
Health Inc, Redwood City, CA), able to estimate the risk of loco-
regional recurrence in node negative, ER positive breast cancer
patients [52]. The threshold score used is 18 for patients to be
classified as low-risk. Five-year loco-regional recurrence rate is
the primary endpoint. Pattern of failure, type of salvage therapy
for local relapse, distant metastases and breast-cancer specific
and overall survival will be collected up to 10-year follow-up [51].
The PRECISION (Profiling Early Breast Cancer for Radiotherapy
Omission) trial is a non-randomized phase II trial (Dana Farber
Cancer Institute-NCT02653755), evaluating the omission of WBI
after lumpectomy in breast cancer patients (aged 50–75) deemed
at favorable-risk and receiving adjuvant endocrine therapy [53].
Inclusion criteria comprise unifocality, size 2 cm, node negativity
after assessment of the axilla, ER and PgR positivity, HER2 negativ-
ity and grade 1–2. Patients aged <50 are excluded because consid-
ered as having a different natural history, as premenopausal
women, and harboring different histologic and biologic tumor
characteristics. Patients over 75 are excluded because of typical
logistic challenges during follow up and competing causes of
death. The trial relies on Prosigna Breast Cancer Assay (NanoString
Technologies Inc., Seattle, WA) for gene expression profiling using
PAM50 gene signature. This test measures the transcriptional pro-
file of 50 classifier genes to generate a clinically validated score for
the 10-year risk of distant recurrence (ROR) [54]. The primary end-
point of the study is 5-year local–regional recurrence rate in the
ipsilateral breast or regional lymph-nodes. Patients stratified as
intermediate- or high-risk will undergo WBI. For those categorized
as low-risk, WBI will be omitted, but endocrine therapy will be
offered. Secondary endpoints are recurrence-free, disease-free
and overall survival. A total of 1380 patients are planned for
accrual [53].
The EXPERT (Examining PErsonalised Radiation Therapy for
Low-risk Early Breast Cancer) trial, run by the Breast Cancer Trial
Group in Australia and New Zealand, with inclusion criteria similar
to the PRECISION trial, will employ Prosigna in order to identify
low-risk breast cancer patients (over 50 years of age, having Stage
I, ER positive, HER2 negative disease). Interestingly, the trial is
designed as a randomised phase III trial [54].
Two other ongoing studies are using IHC to identify breast can-
cer subtypes. Particularly, the so called IHC4 + clinical factors is a
refined immunohistochemical assessment strategy combining pro-
tein expression of ER and PgR, HER2 and Ki-67% with clinic-
pathological features to characterize the risk of recurrence for each
patient [55]. In the TransATAC translational study, ancillary to the
ATAC (Arimidex, TamoxifenAlone or Combined) trial, IHC4 + clinical
factors was able to provide information about prognosis for post-
menopausal women undergoing endocrine therapy [56].
The LUMINA study, a multicentric single-arm prospective
cohort trial (Ontario Clinical Oncology Group-OCOG), investigates
the hypothesis that IHC4 + clinical factors may be able to identify
low-risk patients [57]. The trial evaluates the risk of IBTR after
BCS and sentinel lymph node biopsy/axillary dissection in women
Table 3
New generation trials including those based on biomarker-based patient selection.
Pts: patients; HT: hormonal therapy; RCT: randomized controlled trial; WBI; whole breast irradiation; PBI: partial breast irradiation; BCS: breast conserving surgery; SLNB:
sentinel lymphnode biopsy; AD: axillary dissection; ER: estrogen receptor; PgR: progesteron receptor; HER2: Human Epidermal groeth factor Receptor 2; IHC: immuno-
histochemistry + clinical 4; IBTR: ipsilateral breast tumor recurrence; LRR: local–regional relapse.
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moxifen or aromatase inhibitors). The low-risk population (5- and
10-year IBTR rates < 5% and < 10%, respectively) characteristics are:
negative axilla, Luminal A-like subtype (ER  1%, PgR > 20%, HER2
negative, Ki-67 < 13.25%), size  2 cm, excision margins  1 mm,
with ductal, tubular, mucinous, non-lobular histology, no high
tumor grade (Grade 3) nor lymph vascular invasion or extensive
intraductal component. Five-year rate of IBTR (recurrent, invasive
or in-situ cancer in the ipsilateral breast, histologically proven) is
the primary endpoint of the study. Secondary endpoints are recur-
rence free interval, 5-year event free survival and overall survival.
Up to 500 patients are planned for enrollment [57].
In the United Kingdom, the PRIMETIME trial, a prospective
biomarker-directed case-cohort study plans to enroll 2400 women
aged 60, with T1N0M0 tumors having positive hormonal recep-
tors, negative HER2, and Grade 1–2 [58]. After BCS, sentinel lymph
node biopsy and central testing of Ki-67, patients are planned to be
scored according to IHC4 + clinical factors with a dedicated calcu-
lation algorithm. Those stratified in the ‘very low risk’ category,
will be spared WBI. Complementary endocrine therapy will be
given for 5 years. Primary endpoint is IBTR at 5 years [58].
The future of precision medicine should be based on the inte-
gration of clinical features (patient- and disease-related) with
biomarkers and gene-signatures. An interesting example is the
genomic-adjusted radiation dose (GARD) score, which employs
the gene-expression-based radiosensitivity index and the linear
quadratic model to determine the therapeutic effect of radiother-
apy. This score showed also to be an independent predictor of
radiotherapy-specific outcomes and to be able to estimate the
probability for both relapse- and distant metastasis-free survival
[59].
However, the cost-effectiveness and the reliability of this mul-
timodal assessment will be a major concern to be carefully evalu-
ated within clinical trials and in clinical practice eventually.6. Selective omission of endocrine therapy for patients treated
with BCS and radiation
A high variability in terms of prescription of adjuvant endocrine
therapy after BCS (with or without WBI) can be found in daily prac-
tice, with some clinicians prescribing endocrine therapy whenever
ER positivity is present and others tailoring the indication carefully
evaluating the potential benefit in reducing failure rates compared
to the acute and late treatment-related toxicity profile. The use of
hormonal manipulation affects the risk of recurrence at any site,
including local relapses, and thus affects the absolute benefit of
WBI after BCS. The knowledge on the toxicity profile of hormonal
manipulation is well-established, since side effects of endocrine
therapy could significantly impact long term health-related quality
of life (HRQoL) of potentially frail patients [60].
For a patient population at low-risk of relapse, a de-escalation
of the treatment package may include the omission of endocrine
therapy, instead of WBI, after BCS or even the omission of both
the treatment approaches. Robust data on these options are lacking
and prospective clinical studies are strongly demanded.
The clinical question whether this subset of patients really
needs adjuvant hormonal therapy is still pending. In this sense, a
few trials are being initiated to fulfill this gap.
In the Netherlands, the TOP-1 clinical trial is investigating the
option to omit WBI in a group of EBC patients not receiving adju-
vant endocrine therapy. Although the HRQoL is assessed, the pri-
mary endpoint of the study is local relapse rate [61]. Similarly,
the ongoing Danish Natural trial is evaluating if omission of WBI
in very low risk EBC may provide patients with an equivalent local
control of disease [62].
To our knowledge, the only trial combining a unique primary
endpoint – such as HRQoL – with a cost-effective biomarker assess-
ment (luminal A-like tumor based on IHC) is the phase 2–3
EUROPA trial (NCT04134598). This study will explore the role of
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after BCS for EBC women aged  70 with luminal A-like disease to
determine which of these options may be better in terms of quality
of life [63].7. Conclusions
The challenge to identify the most suitable subset of EBC patient
that can have WBI omitted after BCS is still ongoing. Probably, a
comprehensive integration of features related to patient (age,
comorbid conditions, life expectancy) and tumor, including either
classical factors (size, hormonal receptor status, grade of differen-
tiation and intrinsic subtyping) and genetic andmolecular features,
may enhance our ability to properly identify patients at low-risk of
recurrence. New generation trials will, supposedly, help in answer-
ing this question. Nevertheless, the ideal treatment package for
this potential low-risk patient subgroup still deserves investiga-
tion. Omission of WBI with no adjuvant endocrine treatment after
BCS may consistently increase IBTR rate even in patients with this
recurrence profile. Avoiding radiation in low-risk patients under-
going adjuvant endocrine therapy needs careful consideration as
well. Endocrine therapy may be associated with an increased risk
for osteoporosis with skeletal related events, cardiovascular dis-
ease, sexual dysfunction and even neurocognitive effects [64].
Adjunctively, the impact of endocrine therapy on OS in post-
menopausal patients has yet to be confirmed with even compli-
ance to treatment being rather unpredictable, as only 35–60% of
women accomplish a full 5-year adjuvant program [65]. Treatment
safety and quality of life should also be considered as crucial clin-
ical endpoints and, hence, the need for adjuvant systemic therapy
in low-risk EBC may be debatable. Overall, the side-effects of adju-
vant systemic therapy may outweigh those of WBI, especially con-
sidering that hypofractionation, accelerated partial breast
irradiation and refined delivery techniques have consistently
decreased the radiation-burden in breast cancer patients [66–69].
Composite endpoints evaluating not only IBTR rate and OS but also
the toxicity profile of treatments, patient quality of life, psycho-
social issues, and cost-effectiveness would be indicated to better
tailor the clinical decision-making process in low-risk EBC patients
[70]. A cautionary statement should finally be pointed out, when-
ever considering the omission of a well-established and effective
treatment option, as the recent data on surgery omission in case
of complete response after primary systemic therapy in breast can-
cer patients do confirm [71].Declaration of Competing Interest
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